Expand PALI Menu
PALI MENU

PALI Latest Press Releases

-- November 10, 2026 --

Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs Globe Newswire 4:25 PM

-- October 28, 2026 --

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis Globe Newswire 8:32 AM

-- October 20, 2026 --

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 Globe Newswire 8:05 AM

-- October 12, 2026 --

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn's Disease at ACG 2026 Globe Newswire 8:05 AM

-- September 28, 2026 --

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 Globe Newswire 8:50 AM

-- September 23, 2026 --

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance Globe Newswire 8:45 AM

-- September 22, 2026 --

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD Globe Newswire 8:35 AM

-- September 21, 2026 --

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Globe Newswire 9:00 AM

-- September 3, 2026 --

Palisade Bio to Participate in Upcoming Investor Conferences Globe Newswire 9:00 AM

-- August 10, 2026 --

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Globe Newswire 4:20 PM

-- July 10, 2026 --

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum Globe Newswire 9:00 AM

-- June 29, 2026 --

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes